← SynDRA
ROGINOLISIB
SynDRA canonical compound SYN0038394 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PIK3CD |
|---|
| Mechanism of action | pi3k inhibitor |
|---|
| Indication | lupus |
|---|
| Disease area | rheumatology |
|---|
All known targets
Mechanisms of action (all sources)
- PIK3CD INHIBITOR
- PI3K inhibitor
Cross-references
Synonyms
- IOA-244
- Msc-2360844
- IOA244
- MSC2360844
- Ioa 244
- IOA 244 [WHO-DD]
- compound 339 [US9073940]
- compound 1 [WO2022207646A1]
- compound 339 (US9073940)
- compound 1 (WO2022207646A1)
- RefChem:201854
- 6K8FC2TF54
- roginolisib [INN]
- UNII-6K8FC2TF54
- SCHEMBL12849
- C26H27FN4O5S
- orb1309386
- SCHEMBL29515379
- GTPL12487
- BDBM169989
- GLXC-27265
- EX-A7793
- FCC26737
- NSC827886
- AKOS040733785
- NSC-827886
- DA-55740
- MS-29748
- HY-135827
- CS-0114316
- G17512
- T12115
- US9073940, 339
- MSC2360844 hemifumarate
- UNII-W8JCY5F7F3
- AKOS040756936
- W8JCY5F7F3
- Roginolisib hemifumarate
Look up ROGINOLISIB in the interactive SynDRA portal →